ISVAC™ is Hepatitis C virus-like particle with strong immunostimulatory properties that promise to be efficient in treating Hepatitis C, asthma and other deadly diseases

  • ISVAC™ is coated VLP with size of 30-50 nanometers that is shown to be the most efficient size for endocytosis. ISVAC™ is obtained in BHK-21 cells that provide physiologically relevant conditions for formations of VLP lipoprotein coating
  • ISVAC™ strongly induce serum interferon and stimulate B-cells in response to immunization, thus opening avenues for using ISVAC™ as therapeutics for treatment of interferon-responding and allergy-related diseases.
  • ISVAC™ shows high safety in rodent toxigology and immunotoxicology studies.

image.jpg

  • ISVAC™ is coated VLP with the size of 30-50 nanometers, most optimal for endocytosis

    Despite its recent popularity, uncoated VLPs, such as those of adenovirus and papillomavirus, are known to have several drawbacks. In addition to lacking lipoprotein coating that facilitates receptor interactions, they are too big (70-100 nm) for efficient endocytosis. Our HCV-VLP ISVAC™ succefully fills the void by providing coated VLP with the size of 30-50 nm that is most optimal for endocytosis.

  • ISVAC™ strongly induce serum interferon and stimulate B-cells, while showing high safety in formal rodent toxicology

    As described in our patent and research paper, ISVAC™ displays two distinct immunostimulatory activities. First, ISVAC™ strongly induces serum interferon-alpha upon direct treatment of blood. Second, ISVAC™ strongly stimulates proliferation of B-cell in mice spleen in response to immunization. Both activities are surprising for polyprotein entity as they are known to be induced mostly by nucleic acids interacting with endosomal Toll-receptors TLR3,7-9. Endocytosis is crucial for immunoactivities. HCV-VLP is ideal for endocytosis.

  • ISVAC™ potential applications

    ISVAC™ has several potential applications. The most notable is its strong ability to induce endogenous interferon that is is very promicing in treatment of hepatitis C.
    ISVAC™ ability to stimulate B-cells will be used for creation of novel vaccine adjuvants as well as for treating allergies and asthma.
    Finally, ISVAC™ will be used as RNA delivery tool, capable of including and delivering wide range of RNAs, from siRNA to suicidal contstruct AGP, previously developed by Dr. Sivov.